Skip to content

Agrify Corporation RYM Proceeds From Issuance Of Warrants

Proceeds From Issuance Of Warrants at other companies

Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$2.91M
Replimune Group logo
Replimune GroupREPL
$0-100%
Sidus Space, Inc. logo
Sidus Space, Inc.SIDU
$5.63K
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$3.54M
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$5.86M
ALD
Aldel Financial II Inc.ALDF
$100K

Other financials

Income statement

See full
Revenue$13.3M+2,370%
Gross profit$10.4M+11,452%
Operating income-$4.0M-9.0%
Net income$19.9M+1,325%
EPS (diluted)$1.33+260%

Balance sheet

See full
Cash & equivalents$33.3M+36.0%
Total debt$89.2M+695%
Total equity$36.6M+36.4%
Total assets$127.5M+180%

Cash flow

See full
Operating cash flow$1.0M+116%
CapEx$2.0K+100%
Free cash flow-$1.8M+15.5%

Valuation

See full
Market cap$54.76M+33.2%
Enterprise value$110.74M+43.4%
P/S1.8×

Profitability

See full
Gross margin68.3%
Operating margin-108.8%
Net margin-39%
FCF margin-244.9%+1,014pp

Returns & leverage

See full
Return on equity-36.9%
Debt / equity2.4×+2.0×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by Agrify Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfWarrants.

The official record: Agrify Corporation’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agrify Corporation's proceeds from issuance of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agrify Corporation's proceeds from issuance of warrants?
Agrify Corporation (RYM) reported proceeds from issuance of warrants of $530.75K in Q4 2024.
How has Agrify Corporation's proceeds from issuance of warrants changed year-over-year?
Agrify Corporation's proceeds from issuance of warrants increased by 36.6% year-over-year, from $388.5K to $530.75K.
What does proceeds from issuance of warrants mean?
Represents the cash received from the issuance of financial instruments that grant the holder the right to purchase company stock at a specified price. This metric highlights the company's ability to raise capital through equity-linked instruments.